Actavis is now Allergan
Actavis plc (NYSE: ACT) has completed the acquisition of Allergan, Inc. (NYSE: AGN) in a cash and equity transaction valued at approximately $70.5 billion. The combination creates one of the world's top 10 pharmaceutical companies by sales revenue, with combined annual pro forma revenues of more than $23 billion anticipated in 2015.
Actavis Products in the U.S.
To report adverse events, product complaints, or for medical/product related questions related to Actavis or Watson manufactured U.S. products, call: +1-800-272-5525
To report adverse events and product complaints for Watson, Actavis, Arrow and Warner Chilcott products outside the U.S. please contact the Marketing Authorization Holder for the product. Contact details for Marketing Authorization Holder are listed in the leaflet or labeling accompanying the product.
Actavis Products outside the U.S.